We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+16.13%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$79.9M
AUM Growth
+$6.27M
(+8.5%)
Cap. Flow
-$2.71M
Cap. Flow
% of AUM
-3.39%
Top 10 Holdings %
Top 10 Hldgs %
57.13%
Holding
44
New
13
Increased
11
Reduced
12
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.93M |
| 2 |
KALA BIO
KALA
|
+$1.86M |
| 3 |
Boston Scientific
BSX
|
+$1.86M |
| 4 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$1.8M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$5.88M |
| 2 |
Quest Diagnostics
DGX
|
+$3.21M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$2.36M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$2.01M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
+$1.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$6.13B
| $8.64M | 10.81% |
319,444
-232,114
| -42% | -$5.88M |
|
|
OPTN
2
DELISTED
OptiNose
OPTN
| $6.79M | 8.49% |
22,595
+2,554
| +13% | +$707K |
|
3
Centene
CNC
$29.7B
| $5.16M | 6.45% |
96,552
+4,530
| +5% | +$236K |
|
|
4
Jazz Pharmaceuticals
JAZZ
$16.2B
| $4.73M | 5.91% |
31,304
-13,672
| -30% | -$2.01M |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
| $3.78M | 4.73% |
69,676
+29,346
| +73% | +$1.64M |
|
6
UnitedHealth
UNH
$382B
| $3.75M | 4.69% |
17,518
-2,888
| -14% | -$660K |
|
7
Insmed
INSM
$22.5B
| $3.65M | 4.57% |
162,185
+3,908
| +2% | +$103K |
|
|
8
Quest Diagnostics
DGX
$26.1B
| $3.23M | 4.04% |
32,229
-31,381
| -49% | -$3.21M |
|
9
Natera
NTRA
$36.1B
| $3.02M | 3.77% |
325,529
+125,752
| +63% | +$1.23M |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $2.93M | 3.66% |
194,745
-18,668
| -9% | -$284K |
|
11
Neurocrine Biosciences
NBIX
$18.1B
| $2.47M | 3.09% |
29,825
+5,030
| +20% | +$425K |
|
12
Sarepta Therapeutics
SRPT
$1.62B
| $2.16M | 2.7% |
29,133
-13,992
| -32% | -$933K |
|
13
Heron Therapeutics
HRTX
$89.8M
| $2.13M | 2.67% |
77,346
-21,835
| -22% | -$495K |
|
|
14
KALA BIO
KALA
$11.6M
| $2.13M | 2.66% |
54
+49
| +980% | +$1.86M |
|
15
Syndax Pharmaceuticals
SNDX
$1.73B
| $1.94M | 2.42% |
135,974
+74,444
| +121% | +$790K |
|
|
16
Pfizer
PFE
$144B
| $1.89M | 2.36% |
+56,117
| New | +$1.93M |
|
|
17
Boston Scientific
BSX
$69.5B
| $1.86M | 2.33% |
+68,270
| New | +$1.86M |
|
|
LJPC
18
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $1.66M | 2.08% |
+55,864
| New | +$1.8M |
|
|
DRRX
19
DELISTED
DURECT Corp
DRRX
| $1.61M | 2.02% |
75,277
-12,543
| -14% | -$175K |
|
20
Inogen
INGN
$174M
| $1.53M | 1.92% |
+12,471
| New | +$1.52M |
|
21
Tactile Systems Technology
TCMD
$627M
| $1.35M | 1.69% |
42,460
-629
| -1% | -$19.5K |
|
|
ARRY
22
DELISTED
Array Biopharma Inc
ARRY
| $1.33M | 1.67% |
81,649
+15,554
| +24% | +$249K |
|
23
Puma Biotechnology
PBYI
$400M
| $1.23M | 1.54% |
18,057
+10,686
| +145% | +$800K |
|
24
Penumbra
PEN
$12.6B
| $1.19M | 1.49% |
+10,279
| New | +$1.06M |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| $1.13M | 1.42% |
13,087
-10,698
| -45% | -$864K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, Asymmetry Capital Management held 44 positions worth $79.9M, up 8.5% from $73.7M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Asymmetry Capital Management withdrew a net $2.71M in Q1 2018, closing 8 positions and reducing 12 holdings. Its most notable exit was Invitae Corporation, an estimated $1.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.
Against the trend, Asymmetry Capital Management opened a new position in Pfizer worth $1.89M.
- Asymmetry Capital Management's largest Q1 2018 buy was Pfizer: 56,117 shares worth $1.89M.
- Asymmetry Capital Management added most to KALA BIO in Q1 2018, an estimated $1.86M increase.
- Asymmetry Capital Management's biggest Q1 2018 reduction was PTC Therapeutics, cutting an estimated $5.88M.
- Asymmetry Capital Management fully exited Invitae Corporation in Q1 2018, selling an estimated $1.97M.
- Asymmetry Capital Management's ten largest holdings make up 57% of its $79.9M portfolio in Q1 2018.
- Asymmetry Capital Management opened 13 new positions and closed 8 in Q1 2018.
- Asymmetry Capital Management's portfolio value rose 8.5% quarter-over-quarter to $79.9M.
Based on Asymmetry Capital Management's 13F filing for Q1 2018, filed 9 May 2018.